Jinwon Life Sciences Selected for Ministry of Health and Welfare Technology Development Project with 'SFTS Prevention DNA Vaccine'

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 8th that its severe fever with thrombocytopenia syndrome (SFTS) preventive DNA vaccine GLS-5140 has been selected as a support project in the new vaccine development field for future response to unresolved infectious diseases under the Ministry of Health and Welfare's Vaccine Practical Technology Development Project, and will receive research and development funding up to clinical trial approval.

GeneOne Life Science's SFTS preventive DNA vaccine had already been selected as a support project under the Ministry of Health and Welfare's Infectious Disease Response Technology Development Project, successfully completing the preliminary feasibility evaluation study, publishing the results in the internationally renowned journal Nature Communications, and completing domestic patent registration.

The Vaccine Practical Technology Development Project is a large-scale infectious disease research project planned by the Ministry of Health and Welfare and the Korea Disease Control and Prevention Agency in 2018, aiming to strengthen national health safety and vaccine sovereignty, with a government investment of 215.1 billion KRW over 10 years until 2029. The project team was launched in July.

Park Young-geun, CEO of GeneOne Life Science, said, "Severe fever with thrombocytopenia syndrome is a representative unresolved infectious disease in Korea, with 200 to 300 patients occurring annually, making the development of a vaccine to prevent infection urgent. We will actively utilize our company's global clinical development experience for novel infectious disease vaccines, our proprietary vaccine development platform, and vaccine production capabilities to achieve successful development."

Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease first reported in 2012, continuously occurring in Korea, China, and Japan. With an initial fatality rate of about 30%, it causes organ damage accompanied by hemorrhage. The World Health Organization (WHO) has designated the SFTS virus as one of the priority target pathogens requiring urgent attention.

This content was produced with the assistance of AI translation services.